Cancer Immunoprevention Laboratory


The Cancer Immunoprevention Laboratory focuses on the development and preclinical evaluation of new cancer prevention vaccines and other treatments. 

The laboratory evaluates the immunogenicity of novel vaccines targeted to prevent a variety of cancers including cervical, colorectal, prostate, and several solid tumors. 

The team collaborates with several external and internal organizations, including the Laboratory Animal Science Program. The Cancer Immunoprevention Laboratory is supported by the NCI Division of Cancer Prevention.


Prophylactic cancer vaccine projects 

  • Develop, optimize, and produce vaccines for clinical evaluations. 

  • Collaborate on the evaluation and optimization of RG1, a novel, next-generation VLP-based HPV vaccine that broadens the existing HPV type coverage over current commercially available vaccines. 

  • Evaluate novel peptide-based vaccine for the prevention of Lynch Syndrome, an inherited form of colorectal cancer. 

Chemoprevention projects 

  • Collaborate in preclinical evaluation of gp130 inhibitor molecules. 

  • Develop and establish cell-based assays and in vivo animal models. 

Develop high-sensitivity assays for liquid biomarkers for clinical trial monitoring and early cancer detection 

  • Generate, characterize, and optimize preclinical models to assess disease initiation and progression. 

  • Evaluate lead cancer vaccine candidates or small molecular inhibitors in murine cancer models. 

  • Develop detection of high-sensitivity liquid biomarkers for clinical trial monitoring and early cancer detection. 

  • Develop experimental methods for generating and maintaining in vitro 2D and 3D models and in vivo tumor grafts for screening vaccine candidates. 

  • Use chemoprevention strategies and imaging modalities for disease monitoring in animal models.